1. Home
  2. CVAC

CVAC

CureVac N.V.

Logo CureVac N.V.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-16-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GSK to develop a second-generation covid vaccine. CureVac's first attempt to develop a covid vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.

Founded: 2000 Country:
Germany
Germany
Employees: N/A City: N/A
Market Cap: 651.6M IPO Year: 2020
Target Price: $15.00 AVG Volume (30 days): 774.6K
Analyst Decision: Hold Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.56 EPS Growth: N/A
52 Week Low/High: $2.76 - $12.36 Next Earning Date: 05-28-2024
Revenue: $45,617,021 Revenue Growth: -55.77%
Revenue Growth (this year): -16.12% Revenue Growth (next year): 27.16%

Share on Social Networks: